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Targeted delivery of potent, toxic chemotherapy drugs, such as cisplatin, is a significant area of research in cancer treatment. In this study,
cisplatin was successfully encapsulated with high efficiency (N70%) in poly (lactic-co-glycolic acid) polymeric nanoparticles by using
electrohydrodynamic atomization (EHDA) where applied voltage and solution flow rate as well as the concentration of cisplatin and polymer
were varied to control the size of the particles. Thus, nanoparticles were produced with three different drug:polymer ratios (2.5, 5 and
10 wt% cisplatin). It was shown that smaller nanoparticles were produced with 10 wt% cisplatin. Furthermore, these demonstrated the best
sustained release (smallest burst release). By fitting the experimental data with various kinetic models it was concluded that the release is
dependent upon the particle morphology and the drug concentration. Thus, these particles have significant potential for cisplatin delivery
with controlled dosage and release period that are crucial chemotherapy parameters.
© 2016 TheAuthors. Published by Elsevier Inc. This is an open access article under the CCBY license (http://creativecommons.org/licenses/by/4.0/).
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anticancer agent1,2 that has been shown to be highly effective in
the treatment of testicular, ovarian, breast, bladder, lung and head
and neck cancer. However, due to its significant toxicity, the
maximum dose and hence therapeutic effect in many applica-
tions is restricted.3 Controlled release drug delivery systems
offer a potential means of overcoming the challenges with the
administration and release of anticancer drugs with the optimum
clinical response.4 Numerous controlled release formulations,
e.g. liposomes5 and polymeric particles,6,7 have been proposed
to reduce systemic toxicity.8 Encapsulation within a lipidic or
polymeric particle protects the drug from degradation in theThe authors acknowledge the financial support of the EPSRC (EP/L026287
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tions have shown promise for cellular targeting and prolonged
circulation times.9,10
Poly (lactic-co-glycolic acid) (PLGA) is a biodegradable
polymer that is extensively used in drug delivery systems, due to
its safety profile.11 However, the physico-chemical properties of
cisplatin, in particular its poor solubility in organic solvents,12
pose a considerable challenge in generating a nano-encapsulated
formulation.13 This limits the range of techniques that can be
used for particle fabrication. However, electrohydrodynamic
atomization (EHDA) has been shown recently to facilitate
encapsulation of both hydrophobic and hydrophilic drugs with/1 and EP/L025825/1).
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particle size and size distribution in both the nano and micro
length scales14-16 Controlling the size of the particles results in
adjusting the surface area to volume ratio of particles, enabling
them to penetrate tissue structures.17 Size distribution is also a
crucial factor that provides control over the release profile and
bioavailability of the loaded drug in the body.18 Unlike other
conventional methods that require more than one step to achieve
drug-encapsulated particles, in EHDA, the drug is directly
encapsulated within the polymeric carrier using a single step
procedure.19 Another advantage of EHDA is that volatile
solvents evaporate during particle formation even under ambient
conditions, removing the need for heating or subsequent solvent
extraction that can lead to damage of the particles and/or
degradation of the drug.
In this study, therefore, electrohydrodynamic atomization was
utilized in a single step process to fabricate cisplatin-loaded
particles with high drug encapsulation efficiencies, which can be
used without further treatment. While other drug-encapsulated
materials have been made using this technique,20 there are no
reports of applying this method in manufacturing
cisplatin-loaded biomaterials. A systematic study of variation
of the concentration of both cisplatin and PLGA was conducted,
with the ultimate aim of controlling the dose and release rate of
cisplatin. The influence of nanoparticle morphology, size, and
drug concentration was explored in vitro, with the underlying
delivery mechanism discussed, based on diverse material
characterization and kinetic modeling.Methods
Materials
PLGA (copolymer 50:50, Resomer RG503H, molecular
weight of 33,000 Da, inherent viscosity 0.41 dl g−1) was
supplied from Boehringer Ingelheim (Ingelheim, Germany).
Dimethylacetamide (DMAc) was obtained from Sigma Aldrich
(Poole, UK). Cisplatin (cis-Platinum(ll)diamine dichloride,
molecular weight of 300 g mol−1) was purchased from Enzo
Life Sciences (Exeter, UK).
Particle fabrication
PLGA solutions (2 and 4 wt%) were prepared by dissolving
the polymer in DMAc and mechanically stirring for 400 s.
Cisplatin (either 1 or 2 mg/ml) was then added to the solutions
followed by stirring for a further 500 s in ambient temperature
(20 °C) to ensure the total dissolution of both the drug and
polymer. In order to investigate the effect of cisplatin and PLGA
concentration on the size, morphology and eventually the release
profile of the particles, three different solutions with various
cisplatin to PLGA ratios (2.5, 5 and 10 wt% cisplatin with
respect to PLGA) were prepared. The initial experiments were
conducted with the higher concentration of PLGA (4 wt%).
While the PLGA concentration was kept constant, the amount of
cisplatin added to the solution was increased from 1 to 2 mg/ml
(2.5 and 5 wt% cisplatin with respect to PLGA). A third solution
was prepared with the lower concentration of PLGA (2 wt%) inthe solution while a higher amount of the drug (2 mg/ml, 10 wt%
cisplatin with respect to PLGA) was added to investigate the
morphology and size of the particles as well as the effect of lower
PLGA concentration on the release profile of cisplatin. Finally, a
solution with 4 wt% PLGA without the addition of the drug was
prepared to be used as the control system for the process.
The solutions were electrosprayed using a single needle
EHDA setup (Figure 1) to produce particles. The solutions were
made to flow through a stainless steel needle (18G, ID: 0.84 mm
and OD: 1.27 mm) via a syringe pump (PHD 4400, Harvard
Apparatus Limited, Edenbridge, UK) at a constant flow rate of
2.5, 3, 4 or 5 μl/min. A high precision voltage generator
(Glassman Europe Ltd, Bramley, UK) was used to apply an
electric potential difference between the needle and a ground
electrode to the solution and was varied from 12 to 20 kV as
required to form a stable cone jet. The particles were collected at
a working distance of 200 mm below the device exit directly
onto glass slides or aluminium foil respectively for characteri-
zation and measurement of drug release. Increasing the working
distance lead to reduction in particle size due to longer time for
evaporation of the solvent and therefore allowing columbic
fission to occur even more.17 The working distance in this study
was optimized at 200 mm and it was shown that particles of
desired size upon complete drying were deposited at this
distance. The jet and particle formation processes were
monitored using a Leica DMS300 camera. Experiments were
conducted at the ambient temperature of 19-21 °C and relative
humidity of 40-50%. Each experiment was conducted at least 3
times to ensure the reproducibility of the EHDA process and
consistency of the particles produced.
Characterization of solutions
The viscosity, surface tension, density and electrical conduc-
tivity of all the prepared solutions were measured. Density was
measured using a standard density bottle (DIN ISO 3507 -
Gay-Lussac). Viscosity measurements were conducted using a
U-tube viscometer (size E, VWR, Lutterworth, UK). Prior to
measurements the viscometer was calibrated with ethanol. A
Kruss tensiometer (Model DSA100, Kruss GmbH, Hamburg,
Germany) was used to measure the surface tension (Wilhelmy's
plate method). Electrical conductivity of each solution prepared
was estimated using a conductivity probe (Jenway 3540 pH/
conductivity meter). All the measurements, presented in Table 1,
were conducted at the ambient temperature (21 °C) and relative
humidity of 40-50% after calibrating the equipment with ethanol
or distilled water.
Particle characterization
Optical microscopy and scanning electron microscopy
Samples of particles were collected on glass slides. These
were analysed initially under an optical microscope (Nikon
Eclipse ME 600) fitted with a camera (Micropublisher 3.3 RTV,
3.3 megapixel CCD Color-Bayer Mosaic, Real Time Viewing
camera, Media Cybernetics, Marlow, UK). Further analysis of
particle size and morphology was carried out using the scanning
electron microscope (SEM, XL30 FEG, Philips). Both optical
(bright field) and scanning electron micrographs were analysed
Figure 1. Schematic of the experimental set-up used to prepare drug-loaded particles.
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deviation of the population of particles (300 particles were
measured from each sample). An INCA X-sight EDAX system
(Oxford Instruments) was used with the XL30 microscope for
EDX (Energy dispersive X-ray) spectroscopy analysis to identify
the presence of cisplatin in the nanoparticles.
Fourier transform infrared spectroscopy
The infrared spectra of cisplatin, PLGA nanoparticles, and
drug loaded nanoparticles were recorded using a fourier
transform infrared (FTIR-ATR-Perkin Elmer 2000) spectropho-
tometer. Spectra of all materials were recorded using a frequency
range of 400-4000 cm−1, and averaged over 4 runs. Powdered
samples were placed on the attenuated total reflectance (ATR)
crystal, and then compressed using an axial screw.Table 1
Physiochemical characteristics of the solutions used to prepare particles.
Solution Cisplatin
concentration
with respect
to PLGA
Electrical
conductivity
(μS/cm)
Surface
tension
Viscosity
(mN/m) (mPa s)
2 w/w% PLGA
in DMAc
0 3.65 27 1.62
4 w/w% PLGA
in DMAc
0 3.75 27.5 2.49
0.1 w/w% cisplatin,
4 w/w% PLGA
in DMAc
2.5 wt% 4.45 27.5 2.73
0.2 w/w% cisplatin,
4 w/w% PLGA
in DMAc
5 wt% 4.82 29 2.77
0.2 w/w% cisplatin,
2 w/w% PLGA
in DMAc
10 wt% 13.52 33.5 1.87Transmission electron microscopy
The structural characteristics and cisplatin distribution of the
nanoparticle formulations were examined using a transmission
electron microscope (TEM, CM12, Philips), and EDX analysis
(JEM-2100- Jeol TEM fitted with X-max EDAX system-Oxford
Instruments). For this part of the work, particles were sprayed
directly onto carbon coated copper grids and analysed without
additional contrast.
Differential scanning calorimetry
The endothermic peaks of pure cisplatin, PLGA, and cisplatin
loaded PLGA nanoparticles were recorded using differential
scanning calorimetry (Pyris Diamond DSC, Perkin Elmer
Instruments). 5 mg of the samples were sealed in standard
aluminium pans with lids and analysed over a temperature range
of 0-200 °C.
Drug encapsulation efficiency
In order to determine the encapsulation efficiency of cisplatin,
10 mg of cisplatin-loaded nano/micro particles was mixed with
DMAc followed by addition of PBS. The solution was then
passed through a 0.22 μm filter and analysed by reverse-phase
HPLC method (see in vitro drug release). Encapsulation
efficiency (percentage of the amount of drug added initially
that was entrapped in the nanoparticles) was calculated using
below formula:
Encapsulation efficiency (EE %) = (Wt/Wi) × 100%
Where Wt is the actual drug loading and Wi is the weight of
drug used in particle synthesis.
In vitro drug release
Following a previously published protocol,21 20 mg of
cisplatin loaded nanoparticles were dispersed in 1.5 ml of PBS
(pH 7.4) and incubated at 37 °C. At predetermined time
intervals, 0.5 ml aliquots of solution were removed for the
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Aliquots of the supernatant were centrifuged and analysed using
high performance liquid chromatography (HPLC). Liquid
chromatography was optimised on a Hypersil GOLD SEX
column (Thermo Scientific) under isocratic conditions. A mobile
phase of NaCl soln. (0.9% w/v) and methanol (95:5) was used at
a flow rate of 0.7 ml/min. A calibration plot to calculate the
cisplatin concentrations of unknown measurements was pro-
duced by measuring the absorbance of different concentrations
of cisplatin solution (0.9% w/v saline) from 1 to 50 μg/ml.
The mechanism of drug release from the particles was further
investigated by fitting the kinetic release data to previously
published theoretical models; zero order, first order, Hixson
Crowell, and Ritger-Peppas. These are expressed mathematically
in Eq. (1). Zeroth and first order release kinetics model processes
are independent and directly proportional to the drug concentra-
tion, respectively. First order kinetics could describe release from
a capsule-like particle, in which the drug diffuses through a thin
layer. Another mechanistic-based model, that of Hixson and
Crowell, is used for processes in which dissolution takes place at
the surface of a particle, thereby reducing the size of the particle,
which results in a 2/3-order model.22 Based on the assumption
that the release rate is determined by the diffusion of solute
through the particle, Ritger and Peppas proposed that the release
fraction f (t) up to 60% may be represented by a power law,
where the release exponent is typically slightly less than 0.5:
their expression is a best fit to an exact mathematical result which
depends on the particle radius and the bulk diffusion constant.
Zero order : f tð Þ ¼ A0t
First order : f tð Þ ¼ 1−e−A1t
Hixson and Crowell : f tð Þ ¼
1− 1−AHC tð Þ3if t b 1
AHC
1 if t≥
1
AHC
8><
>:
Ritger and Peppas : f tð Þ ¼ ARPtn
ð1Þ
where n is the release exponent,Ai are fitting parameters, and t is time.
It is worth noting that at short times the zero order, first order and
Hixson and Crowell models all show a release fraction directly
proportional to time,whereas theRitger andPeppas release varies as tn.
The NonlinearModelFit function within Mathematica (Wolfram
Research) was used to fit the release rates of 2.5, 5, and 10 wt%
cisplatin loaded PLGA particles, using the various models,
accounting for the measurement uncertainties by weighting each
data point with the inverse of its associated standard deviation.
Quality of fit was assessed using the adjusted-R2 parameter (the
adjustment allows for different numbers of fitting parameters).Results
EHDA of cisplatin dissolved in PLGA solution
In EHDA, the flow of liquid under the influence of an electric
field undergoes different modes. This is a function of the
operating parameters, primarily: the applied electrical potentialdifference (voltage), the distance between the needle outlet and
the ground electrode as well as the liquid flow rate, needle
diameter and the properties of the flowing liquid.23 At a constant
liquid flow rate and with no electrical field voltage, liquid
droplets will form at the tip of the needle and detach once they
reach a certain volume. Applying a relatively small electrical
potential difference will reduce the diameter of the liquid
droplets formed at the tip of the needle but dripping will
continue. As the applied voltage is increased however, the
atomization mode changes from dripping to jetting.24 The stable
cone jet mode is normally the most desirable atomization mode
as it can produce uniform size particles (Figure A1 in supporting
information). When the applied voltage is slightly higher or
lower than that when a single permanent cone jet is emitted from
the needle tip, the cone jet pulsates.25 While the pulsated cone jet
emits at perfectly timed intervals, the diameter of the cone jet
varies and as a result droplets with different diameters are formed
leading to generation of polydispersed particles (video camera
images and corresponding SEM images are provided in
supplementary information).
In this work, PLGA particles were generated both with and
without cisplatin. Initially, the 4 wt% PLGA solution was
processed to produce drug free particles as the control system to
investigate the effect of cisplatin on the size and morphology of
particles. At a constant flow rate of 5 μl/min, the voltage
required to form a stable cone jet was between 12 and 15 kV
(videos of the cone jet mode are presented in the supplementary
information). Addition of cisplatin influenced the properties of
the solution by increasing the surface tension, viscosity, density
and electrical conductivity. The higher electrical conductivity led
to a higher applied voltage being required at the same flow rate
(5 μl/min) to form a stable cone jet (13-19 kV). Higher or lower
voltages produced an unstable jet and thus non-uniform particles
with a large size distribution.
Particle size and morphology
Experiments were conducted initially with the higher
concentration of PLGA (4 wt%) in the solution and two different
concentrations (2.5 and 5 wt%) of cisplatin with respect to
PLGA. The optical microscope images of the particles are shown
in supplementary Figure A2 and it was noted that larger particles
were produced with the higher concentration of cisplatin
(5 wt%). Detailed SEM images (Figure 2) confirmed that all of
the particles were spherical and with a smooth outer surface. The
concentration of both the polymer and drug was found to
influence the diameter of the cisplatin-loaded particles. Thus, in
order to further reduce the size of the particles, the concentration
of PLGA was reduced to 2 wt% whilst a higher concentration of
cisplatin (2 mg/ml) was added to the solution to giving a drug
concentration of 10 wt% with respect to PLGA. As shown in
Figure 2, at the same flow rate of 5 μl/min, reduced the mean
particle diameter from 1.2 μm to 550 nm (Table 2). It was also
noted that, while the polymer concentration was decreased, the
outer surface of the particles stayed smooth and no pores were
observed in the SEM images. The decrease in the particle size
can be attributed to the lower surface tension, lower viscosity and
higher electrical conductivity of the 10 wt% cisplatin solution
Figure 2. Scanning electron micrographs of particles (A) without cisplatin, (B) 2.5 wt% (C) 5 wt% and (D) 10 wt% cisplatin with respect to PLGA. Size
distribution of particles produced (A) no cisplatin, (B) 2.5 wt% (C) 5 wt% and (D) 10 wt% cisplatin with respect to PLGA.
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Table 2
Operating conditions tested and corresponding size characteristics of particles formed.
Solution Flow rate
(μl/min)
Voltage
(kV)
Particle PDI Yield Encapsulation efficiency
Mean size %
4 w/w% PLGA in DMAc 5 13 950 ± 150 nm 2.8 75% -
0.1 w/w% cisplatin, 4 w/w% PLGA in DMAc 5 14 630 ± 95 nm 2.2 85% 75%
0.2 w/w% cisplatin, 4 w/w% PLGA in DMAc 5 13 1.2 ± 0.2 μm 2.7 75% 70%
0.2 w/w% cisplatin, 2 w/w% PLGA in DMAc 5 16 550 ± 80 nm 2.1 80% 72%
1924 M. Parhizkar et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 1919–1929(values are shown in Table 1). The size distribution of unloaded
and drug loaded polymer particles was characterised by
measuring the diameter of 300 particles randomly chosen from
each sample and the polydispersity indices (PDI) were calculated
(Table 2). Generally, size distribution graphs (Figure 2)
demonstrated a normal size distribution for all the particles
produced. At a constant flow rate of 5 μl/min, particles obtained
from the 10 wt% cisplatin solution also exhibited a lower PDI of
2.1%.
Two important parameters that control the morphology and
size of the electrosprayed particles are voltage and flow rate.26 In
order to overcome the surface tension of the droplet at the tip of
the EHDA needle, high voltage is required to form a stable cone
jet and produce charged droplets. Further experiments were
conducted to demonstrate the ability of EHDA technique to
enable control over the size of particles by adjusting the
processing parameters. In these experiments, the solution with
10 wt% cisplatin was initially infused at a constant liquid flow
rate of 5 μl/min. Once the stable jet is formed, the voltage was
increased from 16 to 19 kV. As shown in size distribution graphs
and microscopic images in Figure 3, the particle mean diameterFigure 3. Optical micrographs and corresponding size distribution graphs for 10 w
stated in Table 3.decreased from 550 nm to 360 nm by increasing the voltage to
19 kV. From size distribution graphs shown in Figure 3, particles
produced with the higher voltage had a narrower size
distribution, while 65% of particles produced had diameters
between 300 and 400 nm.
In a separate study, while the applied voltage was kept
constant at 16 kV, the liquid flow rate was reduced to 3 μl/min
(Table 3). This led to a reduction in the mean particle size to
506 nm. As shown in Figure 3 more than 60% of the particles
produced at the lower liquid flow rate had diameter (Dp) in the
range of 400 bDpb 500 nm. However, decreasing the liquid
flow rate also reduces the rate of particle production. Thus
increasing the applied voltage is likely to be preferable as a
practical means of reducing the particle size.
Characterisation of cisplatin loading
Fourier transform infrared spectroscopy
FTIR spectra were recorded to investigate whether there was
any interaction between PLGA and cisplatin during encapsula-
tion. FTIR spectra of cisplatin, PLGA nanoparticles and PLGAt% cisplatin with respect to PLGA solution at different operating conditions
Figure 4. FTIR spectra of: (A) cisplatin, (B) 10 wt% cisplatin loaded PLGA,
(C) 5 wt% cisplatin loaded PLGA, (D) 2.5 wt% cisplatin loaded PLGA, and
(E) PLGA.
Figure 5. DSC thermogram of (A) cisplatin, (B) 2.5 wt% cisplatin loaded
PLGA, (C) 5 wt% cisplatin loaded PLGA, (D) 10 wt% cisplatin loaded
PLGA, and (E) PLGA (endotherms are indicated as peaks).
Table 3
Operating conditions tested and corresponding size characteristics of
particles formed for 10 wt% cisplatin with respect to PLGA.
10 wt% cisplatin with
respect to PLGA
Flow rate
(μl/min)
Voltage
(kV)
Particle mean
size (nm)
A) 5 19 360 ± 55
B) 3 16 505 ± 70
C) 5 16 550 ± 80
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are shown in Figure 4. The pure cisplatin sample exhibited
characteristic peaks including amine stretching (3271 cm−1),
symmetric amine bending (1292 cm−1) and chloride stretching
(780 cm−1). PLGA nanoparticles showed characteristic peaks
attributable to C=O stretching (1754 cm−1) and C-O stretching
(1050-1250 cm−1). Additionally, the 10 wt% cisplatin loaded
nanoparticles also showed a weak peak for amine stretching
(3294 cm−1), indicating the presence of intact drug (cisplatin).
Thereby the FTIR data indicate that there were no chemical
interactions between PLGA nanoparticles and cisplatin mole-
cules. Furthermore, no peaks corresponding to cisplatin were
observed in the other drug loaded materials, confirming the
reduced quantity of cisplatin in the particles loaded with lower
concentrations of drug.
Differential scanning calorimetry
DSC was performed to assess the physical state of cisplatin
within the PLGA particles (Figure 5). In the thermogram of
PLGA, a glass transition peak was observed at 51 °C; this peak
was not observed in the drug loaded nanoparticle formulations.
An exothermic peak for the drug alone was observed at 281 °C.
The absence of this peak in the cisplatin loaded particles suggests
that the drug is molecularly dispersed in an amorphous form.27
Electron microscopy
The EDX spectra captured during SEM showed the presence
of Cl and Pt peaks for both the 5 and 10 wt% drug loaded
particles, indicating the presence of intact cisplatin (supporting
information Figure A3). This correlates with the FTIR spectra of
the 10 wt% cisplatin materials which indicated the presence of
cisplatin (Figure 4). To further examine the encapsulation and
distribution of cisplatin in the PLGA nanoparticles TEM analysis
was carried out. Micrographs of the nanoparticles loaded with
different cisplatin concentrations (Figure 6, A-C) showed areas
of darker coloration within the particles, indicating regions of
higher density or atomic number (using bright field imaging
mode). In contrast, the particles that were not loaded with
cisplatin (Figure 6, D) appeared even in image intensity,
suggesting that these darker areas in Figures 6, A-C are regions
of cisplatin. TEM-EDX analyses of the cisplatin loaded
(10 wt%) and not loaded PLGA (0 wt%) particles are shown
in Figure 7, it can be seen that peaks for Cl and Pt are present
only in the drug loaded material, correlating with the EDX
analysis described above and confirming the presence of
cisplatin. Furthermore, when comparing EDX spectra from
regions of apparent higher and lower density as indicated on the
micrograph (Figure 7, A), the relative intensity of the peaks
corresponding to Pt and Cl is greatly reduced, and there was a ca.50% reduction in the wt% values calculated for these elements. It
can be concluded that cisplatin was effectively encapsulated
inside the PLGA nanoparticles, and importantly was well
distributed throughout the particle core.
Drug in-vitro release kinetics
To examine the influence of the different cisplatin formula-
tion on the release kinetics, in vitro release of cisplatin
encapsulated in PLGA nanoparticles was observed in PBS at
physiological temperature (37 °C) and pH (7.4). All three
formulations showed a biphasic release, consisting of an initial
burst release (b4 h), followed by a sustained release period due
to loss from drug localised in the PLGA matrix. Generally, burst
release behavior in drug-loaded particles is explained in two
ways: first, initial burst release can occur due to heterogeneous
Figure 6. TEM micrographs of (A) 10 wt%, (B) 5 wt%, (C) 2.5 wt% cisplatin loaded particles, and (D) pure PLGA particle.
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either loosely associated with the surface or embedded in the
surface layer28 and second, release of drug molecules through
the pores and cracks, associated with variation in particle
morphology. Electron micrographs of the drug-loaded particles
indicate that cisplatin was capsulated within PLGA particles by
EHDA (Figure 6), in keeping with the nature of this technique.
Therefore, it can be inferred that the initial burst may have been
caused by the diffusion of embedded cisplatin close to the
surface or through water-filled pores in the PLGA matrix rather
than by surface-bound drug molecules.
An initial sharp release can be desirable for certain delivery
systems, for example targeted delivery or when rapid treatment is
required.29 However, for the most part, avoiding burst release
behavior is desirable to reduce side effects associated with
premature delivery, particularly for highly cytotoxic drugs such
as cisplatin.30 The highest initial release rate was exhibited by
the 5 wt% particles (Figure 8); after 4 h ca. 45% of the initial
cisplatin loaded had been release from the 5 wt% sample,
compared to only 25 and 14% from the 2.5 wt% and 10 wt%
particles, respectively (Figure 8). Therefore, this suggests control
over the burst release may be achieved by controlling the
formulation using EHDA, which is highly important for
cytotoxic drugs as the dosage must be carefully tailored to
each patient to minimize side-effects. Additionally, at the end ofthe time period of the experiment the cumulative cisplatin release
from the PLGA particles correlated with loading amount, also
suggesting control over this property. For example, a total of 329
and 688 μg of cisplatin were released after 144 h from 20 mg of
2.5 and 10 wt% loaded materials, respectively.
To further analyse the mechanism of cisplatin release, the
release data were fitted to the Ritger-Peppas, zeroth, first order,
and Hixson Crowell models. The values of the coefficient of
determination (R2) for the models applied to each formulation
are listed in Table 4. The Ritger-Peppas model provided the best
fit to the release data, with an R2 N0.99 for all the formulations
tested. This suggests that at early times the cisplatin release from
the PLGA particles has a non-linear dependence on time, which
is consistent with diffusive release from distribution throughout
the bulk of the particles. Accordingly, using the approximation
by Ritger-Peppas et al at short times (total release b60%) the
fractional release depends only on one parameter (Dt)1/2/a
(where D is the diffusion constant, t represents time, and a is the
sphere radius).31 Therefore, assuming the diffusion constant
does not vary between materials and drug movement is via
matrix permeation, the rate of release should decrease with
radius. However, this is not in agreement with the cisplatin
release data (Figure 8), from which it can be seen that for
cumulative release b60% the release rate followed the trend
5 wt% particles (1.2 ±0.20 μm) N 2.5 wt% particles (630 ±
Figure 7. EDX spectra and corresponding dark-field scanning transmission electron micrograph indicating sites of analysis for (A) 10 wt% and (B) 0 wt%
loaded PLGA nanoparticles.
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possible to attribute the largest difference in initial release rate
entirely to size using this model, suggesting that something
more complex than a uniform structure with simple permeation
diffusion may exist: perhaps the cisplatin distribution is not so
uniform throughout the particle, or the PLGA matrix may be
slightly different near the surface, leading to a different diffusion
constant.Discussion
The characteristics of polymeric drug delivery systems are
important in determining the release profile of the drug. The
degradation rate of the polymer and consequently the release ofthe drug are affected by the size and shape of the polymeric
particles. The size of the particles may also affect the distribution
of the drug within the polymeric matrix.32 Many of the
properties characterizing the delivery systems are influenced
by the manufacturing methods.33 As demonstrated in Figures 2
and 3, EHDA provides a bottom-up approach in producing
cisplatin-encapsulated particles with precise control over the size
and polydispersity of particles. In this study, cisplatin loaded
PLGA particles of different size have been successfully
synthesised using the highly efficient (encapsulation efficiency
N70%) and controllable EHDA method. Drug loaded PLGA
materials were morphologically controlled by varying the
cisplatin and PLGA concentrations in the solution. Particles
were produced with mean diameters ranging from 100 nm to
1.80 μm and with low polydispersity indices of 2.1-2.8%.
Figure 8. Cumulative release profile of cisplatin from PLGA nanoparticles
loaded with different drug concentrations.
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lation of cisplatin within the polymeric particles. All the
formulations exhibited a two stage release profile in vitro; an
initial burst release b4 h followed by a sustained release period.
This initial burst release may be attributed to the surface/
near-surface loading of the drug that is generally observed in the
drug-loaded polymeric particles produced by single-capillary
electrospray method.16 On the other hand, nanoparticles
encapsulated with 10 wt% cisplatin demonstrated the lowest
initial burst release of approximately 14%, compared to 45% for
the 5 wt% cisplatin microparticles (N4 h), and delivered over
double the mass of drug. This enhanced performance cannot be
explained by simple permeation diffusion kinetics, implying
enhanced functionality due to particle morphology and drug
concentration, which enable the potential for high cisplatin
encapsulation and tunable release.
Drug release from poly(esters) such as PLGA involves two
main mechanisms; diffusion and degradation/erosion.30 Upon
initial contact water adsorption leads to pore formation, which
over time leads to swelling and pore formation large enough for
drug transport.34 Ester bond hydrolysis is an autocatalytic
process in PLGA, which can lead to heterogeneous degradation
driven by an acid gradient, and therefore accelerated diffusion
and erosion processes of the drug and polymer.32 Water
adsorption and drug release rate are governed by a number of
parameters. Importantly, the rate of release is influenced by the
particle size, due to increased pH gradients in larger particles.30
Additionally, the mass of drug encapsulated, and therefore theTable 4
Summary of fits of different kinetic models using R2 values.
Cisplatin
loading
R2
Ritger-Peppas Zeroth-order First-order Hixson-Crowell
2.5 wt% 0.99 0.80 0.95 0.93
5 wt% 0.99 0.55 0.72 0.67
10 wt% 0.99 0.84 0.88 0.87difference in remaining space in the matrix can also affect
release. Consequently, the results from this work indicate that the
drug release from the cisplatin particles is likely a permeation
and pore diffusion-based process, which are dependent upon
particle morphology and drug concentration. The efficient
control of these crucial material properties, afforded by cisplatin
capsulation using EHDA, can lead to control over the drug
dosage and period of release, both of which are essential in
delivery of cytotoxic chemotherapy agents.Acknowledgements
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